Century Therapeutics adds Joseph Truitt to board of directors

Century Therapeutics, Inc. announced on September 9, 2026 that its Board of Directors increased its size from six to seven directors and appointed Mr. Joseph Truitt as a member of the Board, effective as of September 9, 2026.¹ Truitt will serve as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders, and he will sit on the Board's Compensation Committee.¹

Truitt, age 62, has led iECURE, Inc., a gene editing company, as Chief Executive Officer since March 2021, according to the filing. He also holds board roles at Larimar Therapeutics, Inc. since May 2020, and Code Biotherapeutics, Inc. since December 2020.¹ His earlier executive experience includes serving as President, Chief Executive Officer and a board member of Achillion Pharmaceuticals, Inc. from May 2018 until April 2020, when Achillion was acquired by Alexion Pharmaceuticals, Inc.¹, and running BioSpecifics Technologies Corp. as CEO from April 2020 through December 2020, before its acquisition by Endo International plc.¹

As part of his compensation, Truitt will receive an initial option to purchase 148,000 shares of common stock under the company's 2021 Equity Incentive Plan, vesting monthly over 36 months.¹ He will also receive an annual cash retainer of $40,000 as a board member.¹ The Board has determined that Truitt qualifies as an independent director under Nasdaq listing rules.¹

The filing also noted pipeline updates. Century's CEO Brent Pfeiffenberger said Truitt's experience would be useful as the company works toward an IND submission for its type 1 diabetes program, CNTY-813, and clinical entry for CNTY-308, a CAR-iT program, both targeted for milestones this year, according to the company.